Change of plasma PAI-1 and uPA content in polycystic ovarian sysdrome / 基础医学与临床

ABSTRACT

Objective To detect the plasma plasminogen activator inhibitor-1(PAI-1)and urokinase-type plasminogen activator(uPA)levels in PCOS and control of different BMI.Methods This experiment is divided into PCOS group and control group,PCOS group also divided into obesity and without obesity.To assay plasma PAI-1 and serum uPA of PCOS with or without obesity by enzyme-linked immunosurbent assay(ELISA),and to meassure body mass index(BMI),waist hip ratio(WHR),blood glucose,fasting insulin and IRT.To evaluate insulin resistance with Homa Model and to measure insulin area under curve(AUC).Results LH/FSH,T,blood glucose,HOMA-IR,AUC and the plasma level of PAI-1 were significantly increased in PCOS as compared with normal control,and HOMA-IR,AUC and the plasma level of PAI-1 were also increased in obesity as compared with non-obesity of PCOS(P